#ESMO26 | PREDICT-HER – Phase II
Can we biopsy every metastatic lesion in breast cancer? No.
But can we indirectly assess whole-body HER2 expression using HER2-PET? Possibly!
In 89 patients receiving T-DXd, median PFS was 27.5 vs 13.6 months in HER2-PET-positive vs negative patients (HR 0.11).
In HER2-low/zero patients, HER2-PET positivity had a 93.8% positive predictive value for response.
An exciting approach to capturing HER2 heterogeneity and refining patient selection for T-DXd.
424 views · 7 likes · 4 reposts · 0 replies
Early clinical antitumor activity of VRN101099 across diverse HER2-mutants in solid tumors
https://esmocongress.esmo.orgHealth-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.orgSafety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study
https://esmocongress.esmo.orgA global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy in first-line HER2-positive metastatic breast cancer: DESTINY-Breast Guide
https://esmocongress.esmo.orgEfficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgGene-expression profiling of HR+/HER2- breast cancers arising in germline BRCA1/2 mutation carriers
https://esmocongress.esmo.orgSource: Yakup Ergün · x.com